Publication:
DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci.

Loading...
Thumbnail Image

Date

2019-10-19

Authors

Hidalgo-Tenorio, Carmen
Vinuesa, David
Plata, Antonio
Martin-Davila, Pilar
Iftimie, Simona
Sequera, Sergio
Loeches, Belen
Lopez-Cortes, Luis Eduardo
Fariñas, Mari Carmen
Fernandez-Roldan, Concepcion

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

BioMed Central
Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

To analyse the effectiveness of dalbavancin (DBV) in clinical practice as consolidation therapy in patients with bloodstream infection (BSI) and/or infective endocarditis (IE) produced by gram-positive cocci (GPC), as well as its safety and pharmacoeconomic impact. A multicentre, observational and retrospective study was conducted of hospitalised patients with IE and/or BSI produced by GPC who received at least one dose of DBV. Clinical response was assessed during hospitalization, at 3 months and at 1 year. Eighty-three patients with median age of 73 years were enrolled; 73.5% were male; 59.04% had BSI and 49.04% IE (44.04% prosthetic valve IE, 32.4% native IE, 23.5% pacemaker lead). The most frequently isolated microorganism was Staphylococcus aureus in BSI (49%) and coagulase-negative staphylococci in IE (44.1%). All patients with IE were clinically cured in hospital; at 12 months, there was 2.9% loss to follow-up, 8.8% mortality unrelated to IE, and 2.9% therapeutic failure rate. The percentage effectiveness of DBV to treat IE was 96.7%. The clinical cure rate for BSI was 100% during hospital stay and at 3 months; there were no recurrences or deaths during the follow-up. No patient discontinued treatment for adverse events. The saving in hospital stay was 636 days for BSI (315,424.20€) and 557 days for IE (283,187.45€). DBV is an effective consolidation antibiotic therapy in clinically stabilized patients with IE and/or BSI. It proved to be a cost-effective treatment, reducing the hospital stay, thanks to the pharmacokinetic/pharmacodynamic profile of this drug.

Description

MeSH Terms

Aged
Anti-Bacterial Agents
Cost-Benefit Analysis
Drug-Related Side Effects and Adverse Reactions
Endocarditis, Bacterial
Female
Gram-Positive Bacterial Infections
Humans
Length of Stay
Male
Middle Aged
Retrospective Studies
Sepsis
Teicoplanin
Treatment Outcome

DeCS Terms

Tiempo de Internación
Dosificación
Antibacterianos
Sepsis
Endocarditis
Curación en Homeopatía

CIE Terms

Keywords

Bloodstream infection, Dalbavancin, Endocarditis

Citation

Hidalgo-Tenorio C, Vinuesa D, Plata A, Martin Dávila P, Iftimie S, Sequera S, et al. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci. Ann Clin Microbiol Antimicrob. 2019 Oct 19;18(1):30